Prevention & lipidsSecondary analysis
Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia
- Post hoc subanalysis of three clinical studies of evinacumab
- descriptive
Authors' conclusion
This study demonstrated considerable benefit of evinacumab for individuals with HoFH, with or without concurrent LA. Evinacumab appeared to lessen LA burden for some individuals.
Study context
- Population
- Participants with homozygous familial hypercholesterolaemia (HoFH) receiving evinacumab 15 mg/kg in Regeneron-sponsored clinical studies
- Participants
- 138 participants · 3 clinical studies
- Comparison
- Evinacumab with concurrent lipoprotein apheresis (LA) vs without LA
- LA at baselinen = 59
- No LA at baselinen = 79reference
- Primary endpoint
- Mean change in LDL-C from baseline
- Follow-up
- Week 24
Primary result
As reported in the abstract
LDL-C change from baseline
LA
−42.9
mean · SD 23.8 · %
No LA
−50.8
mean · SD 30.5 · %
Further findings
Low-density lipoprotein cholesterol (LDL-C) reduction across timepoints
- Reductions in LDL-C in both subgroups observed across all examined timepoints
Change in LA frequency (LA subgroup)
- LA frequency reduced
- 17 (29%)
- LA frequency increased
- 2 (3%)
Safety
Tolerability
- Evinacumab well-tolerated in both subgroups
Original publication
Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. Published 27 March 2026. doi:10.1093/eurjpc/zwag182
Summarised from the published abstract; every number is checked against it